General Medicines, Medical Department Diabetes Franchise, C/o Oskar Helene Park 33, 14195 Berlin, Germany
Case Report
Response to Insulin Glargine 100 U/Ml Treatment in Newly Identified Type 2
Diabetes Subgroups: Post Hoc Pooled Analysis of Patients in Nine Randomised
Clinical Trials Who Have Never Taken Insulin
Author(s): Wolfang Lagraf*
Aims: To examine the outcomes of the treatment with insulin glargine 100 U/mL (IGlar-100) in newly identified subgroups of type 2 diabetes mellitus (T2DM).
Methods: Participants with insulin-nave T2DM (n = 2684) from nine randomised clinical trials that started IGlar-100 were pooled and put into subgroups called "Mild Age-Related Diabetes (MARD)," "Mild Obesity Diabetes (MOD)," "Severe Insulin Resistant Diabetes (SIRD)," and "Severe Insulin Deficient Diabetes (SIDD)" based on their age at diagnosis, HbA1c, FPG, hypoglycemia, insulin portion, and body weight were examined at standard and 24 weeks.
Results: MARD 15.3 percent (n = 411), MOD 39.8 percent (n = 1067), SIRD 10.5 percent (n = 283), and SIDD 34.4 percent (n = 923). After 24 weeks, the subgroups' adjusted least squ.. View More»
DOI:
10.35248/2155-6156.10001004
